Identifying a Clear Path Through the Changing Maze of AML Management

0.75 CME

0.75 CNE

45 MINS

$0 FEE

Overview

Activity Release Date: June 30, 2023
Activity Expiration Date: June 29, 2024
Estimated time to complete activity: 45 minutes

Provider Statement

Provided by RMEI Medical Education, LLC

RMEI

Target Audience

Hematology, medical oncology, and radiation oncology clinicians managing patients with acute myeloid leukemia (AML)  

Activity Description

Acute myeloid leukemia (AML), the most common form of leukemia, is characterized by a wide range of cytogenetic and molecular aberrations. These aberrations determine risk classification and, if available, targeted therapy. Recent data has changed the diagnostic threshold for AML, as well as risk classification and data on emerging therapies, by reshaping the future of treatment for newly diagnosed and relapsed/refractory AML. Join Drs. Amer Zeidan and Kendra Sweet as they discuss these and other recent updates in AML.

Clinical Transfers

Educational Objectives

Upon completion of this activity, participants should be better able to:

Implement molecular testing at diagnosis and relapse to help guide treatment selection in patients with acute myeloid leukemia (AML) 
Integrate available data on novel therapies into the treatment paradigm of newly diagnosed AML
Utilize current evidence on novel therapies when treating patients with relapsed/refractory AML
Manage the unique adverse events associated with the use of novel therapeutics for AML

Faculty

Amer Zeidan, MBBS, MHS
Associate Professor, Medicine (Hematology)
Yale Cancer Center
Yale University
New Haven, CT

Kendra Sweet, MD, MS
Associate Member, Malignant Hematology Faculty
Medical Director, Clinical Research
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Tampa, FL

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 

Kendra Sweet, MD, MS, has relevant financial relationships with Astellas Pharma, Inc., BerGenBio, Bristol Myers Squibb, Curis, Inc., Gilead, Jazz Pharmaceuticals, MABLYTICS, Inc., Novartis (Consultant); AROG Pharmaceuticals, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals, Loxo Oncology, Inc., MacroGenics, Minneamrita Therapeutics LLC, StemlineTherapeutics Inc. (Grant/Research Support).

Amer Zeidan, MBBS, MHS, has relevant financial relationships with AbbVie, Acceleron Pharma Inc., Agios Pharmaceuticals, ALX Oncology, Amgen, Aprea Therapeutics, Astellas Pharma, Inc., BeyondSpring Pharma, BioCryst Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Cardinal Health, Celgene, Chiesi USA, Inc., Daiichi Sankyo, Epizyme, Inc., Foran, Genentech, Geron Corporation, Gilead, Incyte Corporation, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Jazz Pharmaceuticals, Kura, Mendus, Notable Labs, Novartis, Orum, Otsuka Pharmaceutical Co., Ltd, Pfizer, Seattle Genetics, Servier, Syndax Pharmaceuticals Inc., Syros Pharmaceuticals, Inc., Taiho Pharmaceutical, Takeda, TrovaGene, Inc., Tyme (Consultant); AbbVie, ADC Therapeutics, Amgen, Aprea Therapeutics, Astex, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Celgene, Geron Corporation, Incyte Corporation, MedImmune, Novartis, Otsuka Pharmaceutical Co., Ltd, Pfizer, Shattuck Labs, Takeda, TrovaGene, Inc. (Grant/Research Support); AbbVie, ALX Oncology, BioCryst Pharmaceuticals, Bristol Myers Squibb, Celgene, Geron Corporation, Gilead, Kura, Novartis, Syros Pharmaceuticals, Inc. (Other: Clinical Trial Committees); AbbVie, Acceleron Pharma Inc., Agios Pharmaceuticals, ALX Oncology, Amgen, Aprea Therapeutics, Astellas Pharma, Inc., BeyondSpring Pharma, BioCryst Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Cardiff Oncology, Cardinal Health, Celgene, Chiesi USA, Inc., Daiichi Sankyo, Epizyme, Inc., Foran, Genentech, Geron Corporation, Gilead, Incyte Corporation, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Jazz Pharmaceuticals, Kura, Mendus, Notable Labs, Novartis, Orum, Otsuka Pharmaceutical Co., Ltd, Pfizer, Seattle Genetics, Servier, Syndax Pharmaceuticals Inc., Syros Pharmaceuticals, Inc., Taiho Pharmaceutical, Takeda, TrovaGene, Inc., Tyme (Other: Honorarium); Cardiff Oncology, Novartis, Pfizer (Other: Travel Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

ACCME Jointly accredited In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Method of Participation

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

Read the learning objectives and faculty disclosures
Participate in the activity
Complete the activity evaluation and attest to credit

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Notification Bell Alerts